GGrantIndex
← Search

Development of an Optimized Adjuvanted TB Vaccine

$2,076,197N01FY2022AINIH

University Of Montana, Missoula MT

Investigators

Abstract

Vaccine Adjuvant Discovery Program: To develop a lead, optimized adjuvanted tuberculosis (TB) vaccine for IM or IN administration using specified adjuvants in combination with recombinant or circRNA TB antigens within the context of a vaccine to prevent TB.

View original record on NIH RePORTER →